Reforms to the US’s biosimilars patent litigation create dangers as well as benefits for those seeking to market imitation biologics
7 Jan
2021
Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers
Reforms to the US’s biosimilars patent litigation create dangers as well as benefits for those seeking to market imitation biologics
